ABSTRACT
Primary aldosteronism is a common cause of hypertension, which becomes refractory if undiagnosed, but potentially curable when caused by an aldosterone-producing adenoma (APA). The discovery of somatic mutations and differences in clinical presentations led to recognition of small but common zona glomerulosa (ZG)-like adenomas, distinct from classical large zona fasciculata-like adenomas. The inverse correlation between APA size and aldosterone synthase expression prompted us to undertake a systematic study of genotype-phenotype relationships. After a microarray comparing tumor subtypes, in which NPNT (nephronectin) was the most highly (>12-fold) upregulated gene in ZG-like APAs, we aimed to determine its role in physiological and pathological aldosterone production. NPNT was identified by immunohistochemistry as a secreted matrix protein expressed exclusively around aldosterone-producing glomeruli in normal adrenal ZG and in aldosterone-dense ZG-like APAs; the highest expression was in ZG-like APAs with gain-of-function CTNNB1 mutations, whose removal cured hypertension in our patients. NPNT was absent from normal zona fasciculata, zona fasciculata-like APAs, and ZG adjacent to an APA. NPNT production was regulated by canonical Wnt pathway, and NPNT overexpression or silencing increased or reduced aldosterone, respectively. NPNT was proadhesive in primary adrenal and APA cells but antiadhesive and antiapoptotic in immortalized adrenocortical cells. The discovery of NPNT in the adrenal helped recognition of a common subtype of APAs and a pathway by which Wnt regulates aldosterone production. We propose that this arises through NPNT's binding to cell-surface integrins, stimulating cell-cell contact within glomeruli, which define ZG. Therefore, NPNT or its cognate integrin could present a novel therapeutic target.
Subject(s)
Adrenal Cortex Neoplasms/genetics , Extracellular Matrix Proteins/genetics , Gene Expression Regulation , Hyperaldosteronism/genetics , Kidney Glomerulus/metabolism , Adrenal Cortex/metabolism , Adrenal Cortex Neoplasms/pathology , Adrenal Cortex Neoplasms/surgery , Aldosterone/blood , Cytochrome P-450 CYP11B2/metabolism , Humans , Hyperaldosteronism/pathology , Hyperaldosteronism/surgery , Hypertension/genetics , Hypertension/physiopathology , Immunohistochemistry , Microarray Analysis , Real-Time Polymerase Chain Reaction/methods , Role , Tumor Cells, Cultured , Up-Regulation , Wnt Signaling Pathway/genetics , Zona Glomerulosa/metabolismABSTRACT
El último paso para la producción de aldosterona (11-desoxicorticosterona a aldosterona) en mitocondrias de zona glomerulosa de adrenal de rata es catalizado por la enzima CYP11B2. CYP11B1, en zona fasciculata, transforma 11-desoxicorticosterona en corticosterona o 18-hidroxi-11-desoxicorticosterona. CYO11B1 y CYP11B2 tienen alta homología y sus genes se hallan en tándem en el cromosoma 8q22. Mutaciones en el gen de CYP11B2 y recombinaciones genéticas entre éste y el gen de CYP11B1 serían las responsables de las alteraciones en la enzimología de la producción de aldosterona, dando una nueva denominación y explicación a las deficiencias anteriormente conocidas como de CMOI y CMOII (AU)
Subject(s)
Humans , Animals , Rats , Aldosterone/biosynthesis , Hyperaldosteronism/physiopathology , Cytochrome P-450 CYP11B2/physiology , Cytochrome P-450 CYP11B2/genetics , Steroid 11-beta-Hydroxylase/physiology , Steroid 11-beta-Hydroxylase/genetics , Hyperaldosteronism/classification , Hyperaldosteronism/etiology , Hypertension/complications , Aldosterone/genetics , Glucocorticoids/therapeutic useABSTRACT
El último paso para la producción de aldosterona (11-desoxicorticosterona a aldosterona) en mitocondrias de zona glomerulosa de adrenal de rata es catalizado por la enzima CYP11B2. CYP11B1, en zona fasciculata, transforma 11-desoxicorticosterona en corticosterona o 18-hidroxi-11-desoxicorticosterona. CYO11B1 y CYP11B2 tienen alta homología y sus genes se hallan en tándem en el cromosoma 8q22. Mutaciones en el gen de CYP11B2 y recombinaciones genéticas entre éste y el gen de CYP11B1 serían las responsables de las alteraciones en la enzimología de la producción de aldosterona, dando una nueva denominación y explicación a las deficiencias anteriormente conocidas como de CMOI y CMOII
